Omincom's DDB Worldwide buys PR firm Synergy

Share this article:

Omnicom's DDB Worldwide snapped up London and Philly-based medical communications and PR firm Synergy. 

The shop, which boasts a staff of around 90 split between London and Philadelphia, will be housed in the network's growing DDB Health group. Synergy formed from the 2007 merger of an eponymous med ed firm and healthcare PR shop The Workhouse, and services brands for Pfizer, Merck, Allergan, Roche, Abbott and GSK. 

Founder Gareth Evans said “Everyone is staying on and will be involved in the plan to build Synergy as a truly global business within the DDB network.” The shop will stay put in its existing offices, he added. 

“To be at the heart of the healthcare industry today requires having service capabilities in the scientific arena,” said DDB Worldwide chief Chuck Brymer. “With Synergy as part of the DDB family we are now able to work with pharmaceutical clients from the early stages of a new drug in pre-launch well into the post-launch period. By aligning these two related areas of business, we will offer greater value and innovation to our healthcare clients.” 

The shop will be led by Evans and, in the US, by partner Susan Lohr, and will report to DDB Health UK CEO Ian Dorrian.

“Synergy's global capabilities and market-shaping expertise will dinstinguish the DDB offer from other competitors who do not possess these integrated capabilities in traditional and digital communications,” said DDB Health president Mark Goldstone. “Their established thought leader network and global reach, combined with our professional healthcare and consumer communications skills, will make DDB a unique player in new global medicine launches.” 

Share this article:

Next Article in Features

Email Newsletters

More in Features

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...

Read the complete August 2014 Digital Edition

Read the complete August 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.